$PTCT News
Last published 1w ago
- 1w agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireWARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its
- 1w agoPTCTPTC 3rd Quarter 2026 Financial Results - PTC THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics Third Quarter 2026 Earnings Conference Call. All participants are on a listen-only mode. After the presentation, there'll be a question and
- 1w agoPTCTPTC THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoPTCTPTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsPR Newswire– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue
- 3w agoPTCTPTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PR NewswireWARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a
- 1mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2026, the company approved non-statutory stock options to purchase an...
- 1mo agoPTCTPTC Completes Acquisition of ST-920 Fabry Disease Gene TherapyPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to...
- 1mo agoPTCTMorgan Stanley 24th Annual Global Healthcare Conference - PTC THERAPEUTICS INCEarnings Call TranscriptsAll right, welcome everyone to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Fromer, one of the SMID biotech analysts here. We're very excited to have Matthew Klein and Pierre Gravier with us
- 1mo agoPTCTPTC Therapeutics - 1773653 - PTC THERAPEUTICS INCEarnings Call TranscriptsAll right, welcome everyone to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Fromer, one of the SMID biotech analysts here. We're very excited to have Matthew Klein and Pierre Gravier with us
- 1mo agoPTCTPTC Therapeutics - 1773653 - PTC THERAPEUTICS INCEarnings Call TranscriptsAll right, welcome everyone to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Fromer, one of the SMID biotech analysts here. We're very excited to have Matthew Klein and Pierre Gravier with us
- 2mo agoPTCTPTC Therapeutics to Participate in Upcoming Investor ConferencesPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare ...
- 2mo agoPTCTPTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety ProfilePR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the...
- 3mo agoPTCTPTC Therapeutics Fabry Disease Transaction Call - PTC THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Fabry Disease Transaction Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a que
- 3mo agoPTCTPTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease ProgramPR Newswire– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy for the enzyme
- 3mo agoPTCTPTC 2nd Quarter 2026 Financial Results - PTC THERAPEUTICS INCEarnings Call TranscriptsThis video tutorial shows how to install Kali Linux 2017.1 LXDE on VMware Workstation or VMware Workspace. Kali LXD is a very simple and easy-to-use software that can be installed on your computer. To install it, click o
- 3mo agoPTCTPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026. "Our...
- 3mo agoHLNEPTCTHamilton Lane Board Elects Michael Schmertzler as New Independent DirectorPR NewswireLeading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as...
- 3mo agoPTCTPTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026...
- 4mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an...
- 4mo agoPTCTPTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible NotesPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due...
- 4mo agoPTCTPTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible NotesPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million...
- 5mo agoPTCTGoldman Sachs 47th Annual Global Healthcare ConferencePTC THERAPEUTICS INCEarnings Call TranscriptsOkay, we'll continue with the next session. I'm Paul Choi, and I cover the speed cap biotech sector here at the firm. It's my pleasure to have PTC Therapeutics here, and on stage with me, to my immediate left, Dr. Matthe
- 6mo agoPTCT2026 GLOBAL HEALTHCARE CONFERENCEPTC THERAPEUTICS INCEarnings Call Transcriptswelcome to our next session we've got ptc therapeutics presenting for the next 30 minutes sitting up here on stage with me are a couple folks that you definitely would recognize matt klein who is of course chief executiv
- 6mo agoPTCTPTC 1st Quarter 2026 Financial ResultsPTC THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics' first quarter 2026 earnings conference call. All participants on a listen-only mode. After the speaker's presentation, there will be a Q&A ses
- 6mo agoPTCTPTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026. "We are...
- 6mo agoPTCTPTC Therapeutics to Participate in Upcoming Investor ConferencesPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health...
- 6mo agoPTCTPIVOT-HD Long-Term Extension Study ResultsPTC THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics PivotHD Long-Term Extension Study Top-Line Results Call. All participants are in a listen-only mode. After the presentation, there will be a qu
- 6mo agoPTCTPTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of VotoplamPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension...
- 6mo agoPTCTPTC Therapeutics to Report Results from PIVOT-HD Long Term Extension StudyPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim...
- 6mo agoPTCTPTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial ...
- 6mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an...
- 7mo agoPTCTPTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of DirectorsPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly...
- 8mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an...
- 8mo agoPTCTPTC Therapeutics to Participate at Upcoming Investor ConferencesPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care...
- 8mo agoPTCTPTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December...
- 8mo agoBMRNPTCTPhenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsightPR NewswireRecently published Phenylketonuria Market Insights report includes a comprehensive understanding of current treatment practices, phenylketonuria...
- 9mo agoPTCTPTC Therapeutics Provides Regulatory Update on Translarna™PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren)...
- 9mo agoPTCTPTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year ...
- 10mo agoPTCTPTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare ConferencePR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief...
- 10mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each...
- 10mo agoPTCTPTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in JapanPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that Sephience™ (sepiapterin) has been approved by the Japanese Ministry of Health, Labor and...
- 10mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an...
- 10mo agoPTCTPTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare...
- 11mo agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an...
- 11mo agoCVKDPTCTCadrenal Therapeutics Appoints Dr. Lee Golden to Board of DirectorsGlobeNewswirePONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy,
- 11mo agoPTCTPTC Therapeutics to Host R&D DayPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m. EST in New...
- 1y agoPTCTPTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsPR NewswirePTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025. "We...
- 1y agoPTCTPTC Therapeutics to Participate at Upcoming Investor ConferencesPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: UBS Global Healthcare Conference...
- 1y agoPTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2025, the company approved non-statutory stock options to purchase an...
- 1y agoPTCTPTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial ResultsPR NewswirePTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial ...